Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-08-26. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: transplantationbowelcolitisdose offirst dose
  Phrases that lowered it: patientsinfluenzareceivedparticipantsrange
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 5.4% (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 117 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 551 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 89.4% (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 21.8% (raises risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design
• Design: sequential (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Keywords listed: 12 (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of XmAb23104 in People With Sarcoma NCT05879185 · started 2023 · scored riskier than 57% of active trials terminated
• ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors NCT05277402 · started 2022 · scored riskier than 62% of active trials completed
• SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL NCT04729725 · started 2021 · scored riskier than 71% of active trials terminated
• Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors NCT04096638 · started 2019 · scored riskier than 36% of active trials completed
• Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy NCT05152212 · started 2021 · scored riskier than 26% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.